Sort
3,198 grants matching “mrna vaccine”
Transforming HIV vaccine design with a hybrid technology that leverages features of mRNA and protein nanoparticle platforms
$3,559,750Magnus Adrian Gero Hoffmann · J. David Gladstone Institutes · R01 · FY2025 · AI
Optimal T-cell support for HIV neutralizing antibody induction to fusion peptide-inclusive regimens (Opti-FliP)
$3,552,620Dennis J Hartigan-O'Connor · University Of California At Davis · P01 · FY2025 · AI
Development of rationally designed HIV vaccines
$3,542,953Genoveffa Franchini · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
$3,522,123Barton F Haynes · Duke University · U19 · FY2021 · AI
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
$3,513,157Barton F Haynes · Duke University · U19 · FY2019 · AI
Project 2 - GMP Manufacturing of mRNA Immunogens
$3,489,292Thomas N Denny · Duke University · U19 · FY2021 · AI
Project 5: Multi-scale development and evaluation of broadly-effective vaccines against picornaviruses with pandemic potential
$3,478,173Bert L. Semler · University Of California-Irvine · U19 · FY2024 · AI
MANUFACTURE OF CLINICAL GRADE EPSTEIN-BARR VIRUS VACCINE
$3,460,074Midwest Research Institute · N02 · FY2025 · CA
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
$3,442,683Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2024 · AI
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
$3,420,035Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2022 · AI
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
$3,402,658Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2023 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$3,264,185Richard Childs · National Heart, Lung, And Blood Institute · ZIA · FY2022 · HL
DEVELOPMENT OF A MODIFIED MRNA-BASED VACCINE FOR LASSA VIRUS
$3,253,728University Of Texas Medical Branch At Galveston · · FY2019 · Defense Health Agency
Eliciting neutralizing antibodies and B cell responses using novel HIV Env immunogens in non-human primates
$3,242,006Richard Thomas Wyatt · Scripps Research Institute, The · P01 · FY2021 · AI
CoVPN 3008 Multi-Center, Randomized, Efficacy Study of Early vs Deferred Vaccination with COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern - LC GY18
$3,200,000Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2023 · AI
Administrative Core
$3,194,965Barton F Haynes · Duke University · U19 · FY2020 · AI
CORE D: Animal Models and In Vivo Evaluation Core
$3,193,054Courtney Cohen · Albert Einstein College Of Medicine · U19 · FY2024 · AI
Manufacture an mRNA/LNP encoding an HIV envelope designed to bind and stimulate multiple V2 Apex broadly neutralizing antibody B cell lineages
$3,192,992Barton F Haynes · Duke University · UM1 · FY2024 · AI
Nonhuman primate studies for development of a prototype HIV vaccine that induces broadly neutralizing antibodies
$3,169,510Barton F Haynes · Duke University · UM1 · FY2024 · AI
Allogeneic and Autologous Immunotherapy for cancer and nonmalignant hematological disorders
$3,134,725William Childs · National Heart, Lung, And Blood Institute · ZIA · FY2017 · HL
Enhancing Chimeric Antigen Receptor T Cell Therapies for HematologicMalignancies: Beyond CART 19
$3,119,164Carl H. June · University Of Pennsylvania · P01 · FY2024 · CA
Biodefense and Emerging Infectious Disease Vaccine Studies
$3,109,113Lesia Dropulic · National Institute Of Allergy And Infectious Diseases · ZIA · FY2022 · AI
Optimization of Antibiotics in Mothers and their Breastfed Infants Using Pharmacomicrobiomic and Metabolomic Analyses
$3,069,641Adriana H Tremoulet · University Of California, San Diego · P50 · FY2022 · HD
Nanomedicine Center for Nucleoprotein Machines
$3,054,463Gang Bao · Georgia Institute Of Technology · PN2 · FY2010 · EY
Malaria Vaccines: TBV Antigens as Conjugates with Alternate Carriers
$3,050,048Patrick Duffy · National Institute Of Allergy And Infectious Diseases · ZIA · FY2019 · AI